Teenage acne: what actually clears it, according to the evidence

Teenage acne is common, it is not a sign of poor hygiene, and it responds to treatment that is well established. The strongest evidence points to a small set of first-line options — benzoyl peroxide and topical retinoids, used together and given weeks to work — with oral medicines added for more stubborn cases and oral isotretinoin held back for acne that is severe, scarring, or causing real distress [s1] [s3]. The most common mistake is not the choice of product but the expectation: acne treatments are slow, and stopping early is why many teenagers conclude that "nothing works."

What the guidelines recommend first

The American Academy of Dermatology's 2024 guideline is built from a systematic review graded with the GRADE method, and it issues 18 evidence-based recommendations plus 5 good practice statements [s1]. Its strong recommendations — the highest tier — are for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline [s1]. In other words, the mainstays of treatment are cheap, topical, and mostly available without a specialist.

The guideline also makes a strong recommendation for oral isotretinoin, but with clear limits: it is for acne that is severe, that causes psychosocial burden or scarring, or that has failed standard oral and topical therapy [s1]. Conditional (weaker) recommendations cover newer or more selective options including topical clascoterone, azelaic acid, oral minocycline and sarecycline, combined oral contraceptive pills, and spironolactone [s1]. The distinction between strong and conditional matters: it reflects how confident the evidence lets clinicians be, not a ranking of how "powerful" a drug feels.

Benzoyl peroxide: the workhorse, examined

Benzoyl peroxide is the most widely used topical treatment, and a Cochrane review set out to test how well it actually performs. The reviewers pooled 120 trials, with 29,592 participants randomised across 116 of them [s2]. Most trials studied mild-to-moderate acne (72 trials) rather than severe (26 trials), and the mean age of participants ranged from 18 to 30 years [s2].

For participant-reported improvement, benzoyl peroxide may be more effective than placebo or no treatment, with a risk ratio of 1.27 (95% confidence interval 1.12 to 1.45), based on three trials and 2,234 participants treated for 10 to 12 weeks [s2]. The reviewers rated that as low-certainty evidence, and flagged frequent risk of bias across the literature [s2]. The honest reading is that a treatment used by millions has a solid but not dramatic effect in the trials, and that the evidence base is weaker than its popularity implies.

Combining treatments, and limiting antibiotics

Both the guideline and NICE stress two practical points. First, acne responds best to combinations that hit different mechanisms — for example a topical retinoid with benzoyl peroxide — rather than a single product [s1] [s3]. Second, antibiotics should not do the heavy lifting alone. NICE recommends against using topical or oral antibiotics as monotherapy, and against combining topical and oral antibiotics, precisely because that drives resistance without adding benefit [s3]. The AAD echoes this as good practice: limit systemic antibiotic use and pair it with topical therapy [s1].

NICE frames first-line care around a 12-week course of a fixed combination, reviewed at the end of that period, with referral to a dermatologist for severe acne, scarring, or acne that has not responded to two courses of treatment [s3]. The timeline is the message: judging a regimen before about 12 weeks is judging it too soon.

What this does and does not settle

The evidence supports a clear default: start with topical combinations, add oral treatment for moderate-to-severe or truncal acne, keep antibiotics time-limited, and reserve isotretinoin for the worst or most scarring cases under specialist care [s1] [s3]. What it does not support is the folklore — that acne is caused by dirty skin or chocolate, that scrubbing harder helps, or that a fortnight of any product is a fair trial.

The limits are worth stating. Much of the topical evidence is low-certainty and industry-funded, so effect sizes should be read as directional rather than precise [s2]. Guidelines summarise averages, not individuals, and several strongly recommended drugs carry real cautions — isotretinoin in particular requires pregnancy prevention and monitoring, and combined contraceptives and spironolactone are not options for everyone [s1].

This article is informational and is not medical advice. It does not recommend any medicine or dose for an individual. A teenager with persistent, painful, or scarring acne, or acne that is affecting their mood, should see a GP or pharmacist, who can tailor treatment and refer on where needed.